ISIAMOV 2007 has
provided for display of scientific posters related to the focus of the
symposium. To be considered as a poster presenter, an abstract must be
submitted. All submissions are electronic through the “Abstract
Submission” email address listed at the bottom of this page. We welcome
clinicians, engineers and researchers to submit an abstract of their
work and to display an expanded form as a poster for viewing and
presentation at the symposium.
1. Submission and
• Abstracts must be written in English and submitted via the email
address below. The abstract can be written in text and included as the
body of the email, or can be an attachment of one of the following
forms: Text, MS Word Document(doc or rtf), or PDF file. If you have any
questions about the format of submissions please contact us via the contact page.
• The abstract must concern a subject relevant to the theme of the
• Abstracts will be scored on the following criteria: 1) scientific
merit, 2) originality of work, and .3) adequate sample size and proper
statistical analysis. Submissions with a marketing or commercial focus
are discouraged. Reports containing clinical data must be in compliance
with Good Clinical Practices, EN 540, and as outlined in the U.S. Food
and Drug Administration (FDA) Code of Federal Regulations (CFR):
Section 21, Parts 812.2 (b), 812.3 (m), 821.43(d) and 812.46.
• Submission of an abstract constitutes a commitment by the author(s)
to present the abstract as accepted.
• Posters for accepted abstracts will be continuously displayed during
the symposium. Suggestions for displaying your material in a poster
format will be included in the correspondence to the primary author of
an accepted abstract. All notifications and additional correspondence
will be submitted to the contact author indicated within the abstract
• The abstract and/or information being submitted cannot be previously
presented or published. You may submit new research on a topic that was
previously presented or published.
• The abstract should be organized as follows: (a) a sentence
describing the purpose of the study; (b) a statement of experimental
design or methods used; (c) a summary of results, presented in
sufficient detail to support the conclusion; and (d) a statement of
conclusions reached. Case reports will not follow this format but
should describe the practice, evidence, risk and opportunities
associated with symposium-relevant technology. It is not satisfactory
to state "The results will be discussed . . ." or "Other data will be
presented." Use subtitles to divide sections of an abstract are
encouraged, e.g., methods, results, etc., within the body of the
abstract. Failure to follow this format will result in a low priority
score and may cause rejection of an abstract.
• The body of an abstract is limited to 4,000 characters (including
spaces). The top of the abstract should contain the title, author(s),
and institution(s), all of which is limited to 250 characters
(including spaces). Do not be concerned with font size or style and
page formatting, as these will be managed by the publication group.
Tables, graphics, in text citations, and references may be included but
at the expense of the previously stated character limitation. No
institution or corporate/product logos are allowed. An abstract from
ISIAPO is included as a sample.
• Accepted abstracts will be published as a supplement issue of
Anesthesia and Analgesia, edited by Philip E. Bickler, MD, PhD, and
will also be available at the symposium and on the symposium web site
• Please note that the presenter of a poster must complete normal
registration formalities, i.e., the cost of registration is not waived.
Additionally, expenses associated with the preparation, submission and
presentation of an abstract are the responsibility of the
presenter(s)/author(s). A board to mount the poster and pins to secure
a poster will be provided.
2. Deadline for
submission and timing milestones thereafter
• Abstracts must be submitted by March 4, 2007
• Acknowledgement of the receipt of an abstract will be sent to the
e-mail address of the person identified as the correspondent on the
abstract submission email.
• The notification of selection status of abstracts (i.e., accepted,
accepted pending correction, or rejection) will take place after the
deadline, and candidates will be informed by e-mail.
• You are encouraged to submit before the submission deadline.
• If a correction or alteration to an abstract is desired prior to the
March 4, 2007 deadline, the abstract can be resubmitted. Refer to the
e-mail received as confirmation of submission of the original abstract
and click on the link provided.
• Abstracts can be resubmitted up until the resubmission deadline
stated in the reviewer correspondence.